Teniposide

Teniposide
Clinical data
Trade names	Vumon
Other names	VM-26
AHFS/Drugs.com	Monograph
MedlinePlus	a692045
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
ATC code	L01CB02 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	N/A
Protein binding	>99%
Metabolism	Hepatic (CYP2C19-mediated)
Elimination half-life	5 hours
Excretion	Renal and fecal
Identifiers
	IUPAC name (5R,5aR,8aR,9S)-5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-({4,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl}oxy)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one;
CAS Number	29767-20-2 ;
PubChem CID	34698;
IUPHAR/BPS	6843;
DrugBank	DB00444 ;
ChemSpider	31930 ;
UNII	957E6438QA;
KEGG	D02698 ;
ChEBI	CHEBI:75988 ;
ChEMBL	ChEMBL1200536 ;
CompTox Dashboard (EPA)	DTXSID8023638 ;
ECHA InfoCard	100.045.286
Chemical and physical data
Formula	C32H32O13S
Molar mass	656.66 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(cc(c1O)OC)[C@@H]2c3cc4c(cc3[C@H]([C@@H]5[C@@H]2C(=O)OC5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)COC(O7)c8cccs8)O)O)OCO4;
	InChI InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31?,32-/m0/s1 ; Key:NRUKOCRGYNPUPR-PSZSYXFXSA-N ;
	(what is this?) (verify)

Teniposide (trade name Vumon) is a chemotherapeutic medication used in the treatment of childhood acute lymphocytic leukemia (ALL), Hodgkin's lymphoma, certain brain tumours, and other types of cancer. It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body.